Compare DMRA & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DMRA | BHVN |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2020 | 2022 |
| Metric | DMRA | BHVN |
|---|---|---|
| Price | $24.60 | $8.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $43.00 | $29.08 |
| AVG Volume (30 Days) | 279.5K | ★ 1.6M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.50 | $7.48 |
| 52 Week High | $28.76 | $18.57 |
| Indicator | DMRA | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 48.32 | 39.06 |
| Support Level | $22.71 | $8.08 |
| Resistance Level | $28.00 | $10.57 |
| Average True Range (ATR) | 1.84 | 0.67 |
| MACD | -0.13 | -0.12 |
| Stochastic Oscillator | 52.01 | 7.24 |
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.